Connect with us

Technology

Dandelion Health’s Clinical AI Marketplace Shows GLP-1s May Help Prevent Cardiovascular Disease for 44 Million Previously Unstudied U.S. Patients

Published

1 day ago

on

Dandelion layered validated, unbiased AI from its new Clinical AI Marketplace against its real-world data to demonstrate the potential preventive impact of the GLP-1 drug class for a 7x larger population than those previously studied.

NEW YORK, Sept. 18, 2024 /PRNewswire-PRWeb/ — Dandelion Health, a real-world data (RWD) and clinical AI platform powering next-generation precision medicine and personalized care, announced results today from a large study that demonstrated that GLP-1 medications may be effective as primary prevention for cardiovascular disease (CVD) for 44 million additional at-risk patients who have not been studied until now. The study was conducted using validated AI accessible on Dandelion’s Clinical AI Marketplace, which also officially launched today.

“By combining diverse, multimodal data with validated AI, life sciences companies and researchers can now study treatment effects on a far larger, more representative population — and do so at a fraction of the cost and time…”

Dandelion’s Clinical AI Marketplace enables life sciences organizations to conduct novel scientific research at a fraction of the time and cost of a clinical trial — and far more comprehensively than using traditional RWD typically limited to structured data. Dandelion’s Marketplace also hosts AI algorithms sourced from a rapidly growing ecosystem of clinical AI developers. The company validates those algorithms for performance and equity and runs them on robust, representative RWD to generate rapid, novel insights that researchers can analyze along with all other patient data.

Even though it has an extremely high value, as much as 80% of RWD is unstructured and inaccessible — and found in formats like imaging files, waveforms, and raw clinical notes. Provider notes can, for example, shed light on reasons for treatment discontinuation or symptoms. Medical images (like CTs and MRs) and waveforms can reveal in-depth changes resulting from a new treatment. Dandelion’s Marketplace interprets this siloed data and makes it accessible.

To demonstrate the power of the Clinical AI Marketplace, Dandelion conducted an observational research study to examine a key research question unstudied in clinical trials: Can GLP-1s serve as a primary prevention tool and reduce the risk of heart attacks and strokes among those who do not yet suffer from severe cardiovascular disease?

Dandelion’s study required less than 1% of the time and cost of the clinical trial and was produced in just six weeks using its GLP-1 data library, including a far broader population than possible in clinical trials. For example, Novo Nordisk’s SELECT trial, which demonstrated how semaglutide can reduce major adverse cardiovascular events (MACE), was narrowly focused on obese, non-diabetic adult patients with preexisting severe CVD. Dandelion’s study considered “clinically silent” patients not included in this trial — i.e., those without a past adverse cardiovascular disease event or evidence of preexisting severe cardiovascular disease.

Dandelion used AI to de-risk and accelerate its clinical research. In order to study GLP-1s’ cardioprotective benefits, Dandelion used an AI-biomarker algorithm developed by Pheiron that predicts the risk of MACE using raw ECG waveforms collected during regular clinical care. The company also leveraged its public validation service to ensure the algorithm was high-performance and unbiased.

“The combined power of real-world data and AI has the potential to reshape how life sciences conduct clinical trials and research,” said Shivaani Prakash, MSc, PhD, Head of Data at Dandelion Health. “By combining diverse, multimodal data with validated AI, life sciences companies and researchers can now study treatment effects on a far larger, more representative population — and do so at a fraction of the cost and time.”

In this study, for example, Dandelion used AI to model predicted MACE risk reduction from GLP-1s, rather than wait for adverse events to actually occur. Its findings indicate that GLP-1s result in 15%–20% lower MACE risk among patients after three years, as compared to similar patients not taking GLP-1s. A previously unstudied population of 44 million additional patients may experience these cardioprotective benefits1. If this broader group of patients were to take a GLP-1, this could potentially result in 34,000 fewer myocardial infarctions and strokes annually.

“The cost and time associated with drug development and commercialization are substantial, but the impact of providing the right treatment to the right patient, and doing so with unprecedented speed, is immeasurable for the billions of people who depend on innovative drugs and therapies,” said Elliott Green, Co-founder and CEO of Dandelion Health.

Similar research may enable life sciences companies to de-risk future clinical trials, compare various treatments head-to-head, and support market access and reimbursement decisions. These types of insights also enable providers to select the right treatment for their patients at the right time, enabling earlier intervention and reducing avoidable adverse health outcomes.

To learn more about Dandelion’s Clinical AI Marketplace and the value it can provide for life sciences companies, please visit https://dandelionhealth.ai/clinical-ai-marketplace.

About Dandelion Health

Dandelion Health is a real-world data (RWD) and clinical AI platform powering next-generation precision medicine and personalized care. Dandelion’s platform delivers novel clinical insights at scale from rich, multimodal patient data – enabling AI, medical device and life sciences companies to accelerate the entire product development lifecycle, improving clinical outcomes and enhancing patient lives. Founded by the world’s leading experts in healthcare and AI, Dandelion is a diverse and growing consortium of leading healthcare systems from across the United States. To learn more, visit www.dandelionhealth.ai.

Media Contact

KT McGraw, Dandelion Health, 1 7818792395, media@dandelionhealth.ai, https://dandelionhealth.ai/ 

View original content to download multimedia:https://www.prweb.com/releases/dandelion-healths-clinical-ai-marketplace-shows-glp-1s-may-help-prevent-cardiovascular-disease-for-44-million-previously-unstudied-us-patients-302251225.html

SOURCE Dandelion Health

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Dana-Farber Cancer Institute Partners with Clinical.ly to Enhance Regulatory Operations with eReg Solutions

Published

40 mins ago

on

September 19, 2024

By

NEW YORK, Sept. 19, 2024 /PRNewswire/ — The Dana-Farber Cancer Institute, a world leader in cancer treatment and research, chose Clinical.ly’s (www.clinical.ly) Research Suite™ to streamline regulatory operations, marking a significant step toward more efficient and compliant clinical trial management. Dana-Farber joins a growing number of research organizations that leverage Clinical.ly’s innovative solutions to streamline clinical trial processes. Clinical.ly’s eReg platform offers a comprehensive, paperless solution that centralizes regulatory workflows, ensuring compliance and transparency across clinical trials.

“We are thrilled to support Dana-Farber’s clinical research operations,” said Henry Kravchenko, Clinical.ly’s CEO.

This partnership continues Clinical.ly’s success in providing best-in-class enterprise tools for conducting clinical research. “We are thrilled to support Dana-Farber’s clinical research operations,” said Henry Kravchenko, Clinical.ly’s CEO. “Our eReg platform and wider set of features in Clinical.ly Research Suite™ will empower that renowned organization, and we all look forward to supporting their teams.”

About Clinical.ly Research Suite™ 

Clinical.ly Research Suite™ is a comprehensive solution that eliminates traditional, paper-based processes. By automating and centralizing essential workflows in the Clinical.ly Research Suite™, organizations achieve huge efficiency improvements, greater trial oversight, document management, and regulatory compliance. The Clinical.ly Research Suite™ includes:

eReg: A best-in-class electronic regulatory bindereSource: An intuitive & feature-rich, paperless data capture solution that streamlines data collection from trial participantseConsent: A fully digital solution for capturing informed consent, improving participant engagement and site complianceClinicallySign: 21 CFR Part 11 compliant eSignature functionalityClinicallyPay: A secure and instantaneous participant stipend payment and reimbursement solution

About Dana-Farber Cancer Institute

Founded in 1947, Dana-Farber Cancer Institute is committed to providing adults and children with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Based in Boston, Dana-Farber is a teaching affiliate of Harvard Medical School and ranks consistently as one of the top cancer hospitals in the world.

About Clinical.ly

Clinical.ly provides differentiated, cloud-native technology solutions to the clinical research industry, enabling research organizations to conduct studies with greater efficiency and ease. Clinical.ly is dedicated to developing technology that eliminates tedious manual labor, allowing clinical research professionals to focus on patient care.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dana-farber-cancer-institute-partners-with-clinically-to-enhance-regulatory-operations-with-ereg-solutions-302253690.html

SOURCE Clinical.ly

Continue Reading

Technology

Fall Into Creativity with the Monport Laser Fall Sale

Published

40 mins ago

on

September 19, 2024

By

NEW YORK, Sept. 19, 2024 /PRNewswire/ — Experience laser innovation this Fall with Monport Laser, an industry frontrunner in laser engraving and cutting technology, with an exclusive Fall Sale offering incredible discounts and free accessories on a wide range of high-performance laser engraving machines. From September 19th to September 30th, customers can take advantage of this limited-time opportunity to elevate their laser engraving businesses with cutting-edge laser innovation at unbeatable prices.

Monport Laser has been dedicated to providing innovative and reliable laser machines that empower businesses and individuals to achieve their goals. With a focus on quality, precision, and customer satisfaction, Monport Laser has established itself as a trusted leader in the industry. Their commitment to excellence is evident in every laser they produce, ensuring exceptional performance, reliability, and value.

Embrace the Power of CO2 Laser Technology with Exclusive Offers

Monport Laser will offer two free accessories with selected CO2 laser machines during the Monport Fall sale. These versatile lasers are ideal for various applications, including engraving, cutting, and marking wood, acrylic, leather, and more. By taking advantage of this Fall sale, laser engraving businesses can enhance their productivity and expand their creative possibilities.

Experience Unmatched Value with Fiber Laser Discounts

Monport Laser offers substantial discounts of up to $4200 and 3 free accessories on selected models for those seeking the precision and speed of fiber laser technology. Fiber lasers are renowned for their ability to process metals with exceptional efficiency and accuracy, making them indispensable for metal fabrication, manufacturing, and jewelry production. Additionally, customers purchasing fiber lasers during the Fall sale will receive three free accessories, further sweetening the deal.

Elevate Your Desktop Laser Experience with a Free Water Chiller

Monport Laser is committed to providing comprehensive solutions for businesses of all sizes. As part of the Fall sale, customers who purchase the 40W Desktop laser will receive a Free Water Chiller Cw3000. This essential accessory ensures optimal cooling and performance, prolonging the lifespan of the laser and guaranteeing consistent results.

Discover Additional Savings on a Wide Range of Accessories

Monport Laser offers an additional 20% discount on selected accessories to complete your laser setup. From lenses and nozzles to rotary tables and smoke extraction systems, customers can find everything they need to maximize the potential of their laser machines.

Unleash Your Creativity and Productivity

Monport Laser’s Fall sale is the perfect opportunity to invest in laser technology that empowers your business or fuels your creative passions. With exceptional discounts and free accessories, you can acquire the ideal laser solution to meet your needs and budget.

Whether you’re an entrepreneur, artist, or manufacturer, Monport Laser’s advanced laser machines offer unparalleled precision, versatility, and reliability. Take advantage of this limited-time Fall sale and unlock your projects’ full potential for laser innovation.

About Monport Laser

Monport Laser is a global leader in designing, manufacturing, and distributing high-quality laser machines and accessories. With a commitment to innovation and customer satisfaction, Monport Laser provides cutting-edge solutions for various industries, including manufacturing, engraving, marking, and more.

For more information, visit monportlaser.com and follow them on social media for the latest updates.

Website: https://www.monportlaser.com/

 

 

 

View original content:https://www.prnewswire.com/news-releases/fall-into-creativity-with-the-monport-laser-fall-sale-302253699.html

SOURCE Monport Laser

Continue Reading

Technology

MEDIA ADVISORY – Minister Wilkinson to Make a Critical Minerals Infrastructure Announcement

Published

40 mins ago

on

September 19, 2024

By

VANCOUVER, BC, Sept. 19, 2024 /CNW/ – The Honourable Jonathan Wilkinson, Minister of Energy and Natural Resources, and Ranj Pillai, the Premier of Yukon, will make a funding announcement in support of critical minerals infrastructure projects. A media availability will follow.

Date: September 20, 2024

Time: 10:30 a.m. PT

All accredited media are asked to pre-register by emailing media@nrcan-rncan.gc.ca. A dial-in line is available for media and will be provided upon registration.

Follow us on LinkedIn

SOURCE Natural Resources Canada

Continue Reading

Trending